GLP-1s After Cancer: 10 Studies for a Population the Trials Excluded

10 papers · each one re-checked on PubMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The obesity trials excluded most people with active or recent cancer, which means the efficacy figures quoted everywhere else on this site were not measured in this population. Nothing below is a randomized trial in survivors, because none has been run. The questions survivors and their oncologists ask are also different from the ones the obesity trials answered: how much of the weight gained on an aromatase inhibitor or on tamoxifen can be reversed, whether the muscle-wasting obesity that follows androgen-deprivation therapy behaves like ordinary obesity, and whether reducing weight lowers the elevated cardiac risk that follows cancer treatment. The strongest entries here are two survivor-specific cohorts and a population study showing that substantial weight gain after breast cancer raises cardiovascular risk. Several papers on this page contribute by documenting what has not been studied. In a field this new that is a real contribution, but it is not evidence that the drugs work here.

Ranked papers

#1

Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Sukumar JS, Raghavendra AS, Pasyar S, et al. · Cancer Res Commun · 2026

What it measured: Weight and clinical outcomes in breast cancer survivors who started the drug

The most directly relevant dataset published: a cancer-center cohort of 1,022 survivors of nonmetastatic breast cancer who took a GLP-1 drug between 2005 and 2024, 79% of them with type 2 diabetes. Among the 442 on semaglutide or tirzepatide, median weight change was only −1.9% at three months, −3.1% at six and −2.6% at a year, far below what the registration trials report, and endocrine therapy was linked to weight gain. Against matched nonusers, GLP-1 users had better overall survival (hazard ratio 0.37) but no difference in disease-free survival. It is observational, with no placebo group.

PMID 41677473 ↗DOI 10.1158/2767-9764.CRC-25-0554 ↗

#2

Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer

Cornelio CK, Cowart K, Perkins J, et al. · Pharmacotherapy · 2026

What it measured: Cardiac events among women carrying breast cancer alongside type 2 diabetes

The first cardiovascular outcomes analysis limited to women who have type 2 diabetes as well as breast cancer, comparing those who started a GLP-1 against those started on other diabetes drugs in a large claims dataset. Fewer cardiovascular events on the GLP-1, consistent with what the big trials show in the general population. Confounding by indication is the live problem here, and cancer stage, which drives both prognosis and prescribing, was incompletely captured. It is a bridge to a trial, not a substitute for one.

PMID 41801847 ↗DOI 10.1002/phar.70130 ↗

#3

Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer

Wooster M, Chen L, Accordino MK, et al. · Breast Cancer Res Treat · 2025

What it measured: Cardiovascular event incidence by weight-management treatment utilization

An examination of who receives weight-management treatment after breast cancer (drugs, surgery or behavioral programs) and what happens to their cardiovascular risk afterward. Its limitation is a matter of timing: the data end in 2021, before access to these drugs widened sharply, so the treatment mix it describes is already historical. It is most useful for the disparity question, which is who gets offered anything at all.

PMID 40360855 ↗DOI 10.1007/s10549-025-07714-6 ↗

#4

Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015

Lopez DS, Abdelgadir O, Zhang Y, et al. · Obesity (Silver Spring) · 2026

What it measured: Heart disease rates by whether women took a weight drug and had prior cancer

A SEER-Medicare study of 46,552 women aged 65 and over, half of them survivors of an obesity-related cancer and half matched cancer-free women, drawn from 2007 to 2015, when the modern drugs barely existed. Use of the older weight-loss drugs was associated with less heart disease overall (hazard ratio 0.80). Among survivors, the association pointed the same way but reached significance only in the per-protocol analysis (0.74). Read it as a baseline from the pre-GLP-1 era rather than as evidence about GLP-1s, which the authors say need their own studies.

PMID 42083112 ↗DOI 10.1002/oby.70211 ↗

#5

Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study

Jung W, Park SH, Park YM, et al. · Breast Cancer Res Treat · 2025

What it measured: Heart disease rates by how much weight changed after a cancer diagnosis

The strongest population-level evidence here, and it tests no drug at all. Using Korean national insurance data on 42,547 survivors, it tracked how weight change after a breast cancer diagnosis relates to later heart attack and stroke. Gaining more than 10% raised the risk (adjusted hazard ratio 1.66) against keeping weight stable, and sustained obesity carried more risk in survivors under 50 and in those on tamoxifen. It shows the cost of weight gain. Whether deliberate weight loss lowers the risk is what the authors say intervention studies, such as GLP-1 trials, now need to test.

PMID 39762706 ↗DOI 10.1007/s10549-024-07594-2 ↗

#6

Embracing Highly Effective Obesity Therapies to Improve Cancer Treatment and Survivorship

Howard R, Pilewskie M, Dossett LA · JAMA Oncol · 2026

What it measured: Narrative synthesis

An editorial arguing that oncology has been slow to bring effective obesity treatment into cancer care across prevention, treatment and survivorship, and setting out the trials, guidelines and coverage barriers standing in the way. It contains no new data, and it is a short Viewpoint focused on how rarely survivors are offered GLP-1 drugs or bariatric surgery.

PMID 41954902 ↗DOI 10.1001/jamaoncol.2026.0260 ↗

#7

Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health

Hundal J, Chen J, Russell KB, et al. · Am Soc Clin Oncol Educ Book · 2026

What it measured: Narrative review

A survivorship-curriculum chapter integrating lifestyle, weight management and psychological care after breast cancer, and one of the first mainstream oncology-education sources to name these drugs as a survivorship tool rather than strictly an obesity-medicine one. Educational positioning is not a guideline endorsement, and the chapter stops deliberately short of one. If a survivor asks whether their oncology society backs this use, this is the accurate answer to give them.

PMID 42127339 ↗DOI 10.1200/EDBK-26-517396 ↗

#8

Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options

Fore-Williams L, Distler M · J Adv Pract Oncol · 2026

What it measured: Narrative review

The only review focused on tamoxifen-associated weight gain specifically, a problem affecting a large share of premenopausal survivors across five to ten years of therapy and one rarely addressed on its own. It covers lifestyle and drug options, and how the moment you intervene interacts with endocrine therapy still in progress. Its most valuable feature is candor: it states outright that no randomized data exists in this exact population, and offers a practical approach anyway.

PMID 42170166 ↗DOI 10.6004/jadpro.2026.17.3.3 ↗

#9

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, et al. · JNCI Cancer Spectr · 2026

What it measured: Systematic review

A systematic review of diet, nutrition and hormone therapy in prostate cancer, and the closest published synthesis of the androgen-deprivation weight problem. That therapy reliably drives visceral fat gain, muscle loss, insulin resistance and elevated cardiovascular mortality, a combination that plausibly responds differently to these drugs than ordinary obesity does. The authors map what has been tried, note that no dedicated randomized trial exists in men on this therapy, and call for one. That call is the paper's contribution.

PMID 41703670 ↗DOI 10.1093/jncics/pkag014 ↗

#10

Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer

Kajitani N, Takahashi J, Honda H, et al. · Intern Med · 2020

What it measured: Case description

A single case report, included as illustration rather than evidence: a 79-year-old man who developed severe visceral obesity, fatty liver and new type 2 diabetes within eight months of surgical removal of the testes for prostate cancer. Treatment with canagliflozin and the GLP-1 drug dulaglutide improved his blood sugar, visceral fat and fatty liver, and the authors suggest that combination may help after this surgery. It is one patient, and the authors note his visceral-fat pattern differed from the usual course after androgen deprivation, but it shows the metabolic problem this whole question is about.

PMID 32522924 ↗DOI 10.2169/internalmedicine.4653-20 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.